250 related articles for article (PubMed ID: 27318987)
1. Abuse potential of methylenedioxymethamphetamine (MDMA) and its derivatives in zebrafish: role of serotonin 5HT2-type receptors.
Ponzoni L; Braida D; Sala M
Psychopharmacology (Berl); 2016 Aug; 233(15-16):3031-9. PubMed ID: 27318987
[TBL] [Abstract][Full Text] [Related]
2. Ritanserin-sensitive receptors modulate the prosocial and the anxiolytic effect of MDMA derivatives, DOB and PMA, in zebrafish.
Ponzoni L; Sala M; Braida D
Behav Brain Res; 2016 Nov; 314():181-9. PubMed ID: 27506653
[TBL] [Abstract][Full Text] [Related]
3. The Non-Peptide Arginine-Vasopressin v
Ponzoni L; Braida D; Bondiolotti G; Sala M
Front Psychiatry; 2017; 8():146. PubMed ID: 28855876
[TBL] [Abstract][Full Text] [Related]
4. Hallucinatory and rewarding effect of salvinorin A in zebrafish: kappa-opioid and CB1-cannabinoid receptor involvement.
Braida D; Limonta V; Pegorini S; Zani A; Guerini-Rocco C; Gori E; Sala M
Psychopharmacology (Berl); 2007 Mar; 190(4):441-8. PubMed ID: 17219220
[TBL] [Abstract][Full Text] [Related]
5. Potent agonist activity of DOB at 5-HT2 receptors in guinea pig trachea.
Heller WA; Baraban JM
Eur J Pharmacol; 1987 Jun; 138(1):115-7. PubMed ID: 3622603
[TBL] [Abstract][Full Text] [Related]
6. Role of AMPA glutamate receptors in the conditioned rewarding effects of MDMA in mice.
García-Pardo MP; Miñarro J; Aguilar MA
Behav Brain Res; 2018 Jul; 347():57-60. PubMed ID: 29526785
[TBL] [Abstract][Full Text] [Related]
7. Reinforcing effects of certain serotonin-releasing amphetamine derivatives.
Marona-Lewicka D; Rhee GS; Sprague JE; Nichols DE
Pharmacol Biochem Behav; 1996 Jan; 53(1):99-105. PubMed ID: 8848466
[TBL] [Abstract][Full Text] [Related]
8. A preliminary investigation of the psychoactive agent 4-bromo-2,5-dimethoxyphenethylamine: a potential drug of abuse.
Glennon RA; Titeler M; Lyon RA
Pharmacol Biochem Behav; 1988 Jul; 30(3):597-601. PubMed ID: 3211969
[TBL] [Abstract][Full Text] [Related]
9. Effects of MDMA exposure on the conditioned place preference produced by other drugs of abuse.
Cole JC; Sumnall HR; O'Shea E; Marsden CA
Psychopharmacology (Berl); 2003 Apr; 166(4):383-90. PubMed ID: 12601504
[TBL] [Abstract][Full Text] [Related]
10. Effects of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') and para-methoxyamphetamine on striatal 5-HT when co-administered with moclobemide.
Freezer A; Salem A; Irvine RJ
Brain Res; 2005 Apr; 1041(1):48-55. PubMed ID: 15804499
[TBL] [Abstract][Full Text] [Related]
11. Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat.
Daws LC; Irvine RJ; Callaghan PD; Toop NP; White JM; Bochner F
Prog Neuropsychopharmacol Biol Psychiatry; 2000 Aug; 24(6):955-77. PubMed ID: 11041537
[TBL] [Abstract][Full Text] [Related]
12. Hallucinogenic and stimulatory amphetamine derivatives: fingerprinting DOM, DOI, DOB, MDMA, and MBDB by spectral analysis of brain field potentials in the freely moving rat (Tele-Stereo-EEG).
Dimpfel W; Spüler M; Nichols DE
Psychopharmacology (Berl); 1989; 98(3):297-303. PubMed ID: 2568652
[TBL] [Abstract][Full Text] [Related]
13. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens.
Titeler M; Lyon RA; Glennon RA
Psychopharmacology (Berl); 1988; 94(2):213-6. PubMed ID: 3127847
[TBL] [Abstract][Full Text] [Related]
14. Chronic treatment with a serotonin(2) receptor (5-HT(2)R) agonist modulates the behavioral and cellular response to (+)-3,4-methylenedioxymethamphetamine [(+)-MDMA].
Ross JD; Herin DV; Frankel PS; Thomas ML; Cunningham KA
Drug Alcohol Depend; 2006 Feb; 81(2):117-27. PubMed ID: 16054778
[TBL] [Abstract][Full Text] [Related]
15. Rewarding effects of the optical isomers of 3,4-methylenedioxy-methylamphetamine ('Ecstasy') and 3,4-methylenedioxy-ethylamphetamine ('Eve') measured by conditioned place preference in rats.
Meyer A; Mayerhofer A; Kovar KA; Schmidt WJ
Neurosci Lett; 2002 Sep; 330(3):280-4. PubMed ID: 12270646
[TBL] [Abstract][Full Text] [Related]
16. Rewarding effects and reinstatement of MDMA-induced CPP in adolescent mice.
Daza-Losada M; Ribeiro Do Couto B; Manzanedo C; Aguilar MA; Rodríguez-Arias M; Miñarro J
Neuropsychopharmacology; 2007 Aug; 32(8):1750-9. PubMed ID: 17299518
[TBL] [Abstract][Full Text] [Related]
17. Behavioural and neurochemical effects of combined MDMA and THC administration in mice.
Robledo P; Trigo JM; Panayi F; de la Torre R; Maldonado R
Psychopharmacology (Berl); 2007 Dec; 195(2):255-64. PubMed ID: 17684733
[TBL] [Abstract][Full Text] [Related]
18. Involvement of 5-hydroxytryptamine 5-HT₃ serotonergic receptors in the acquisition and reinstatement of the conditioned place preference induced by MDMA.
Roger-Sánchez C; Rodríguez-Arias M; Miñarro J; Aguilar MA
Eur J Pharmacol; 2013 Aug; 714(1-3):132-41. PubMed ID: 23792143
[TBL] [Abstract][Full Text] [Related]
19. [3H]DOB: a specific agonist radioligand for 5-HT2 serotonin receptors.
Titeler M; Herrick K; Lyon RA; McKenney JD; Glennon RA
Eur J Pharmacol; 1985 Oct; 117(1):145-6. PubMed ID: 4085543
[No Abstract] [Full Text] [Related]
20. Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP.
Tancer M; Johanson CE
Drug Alcohol Depend; 2003 Oct; 72(1):33-44. PubMed ID: 14563541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
